U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07095049) titled 'Safety, Tolerability, and Systemic Exposure of Apo-Si- K170A-C76 in Healthy Volunteers' on June 22.
Brief Summary: The goal of this First in Human Phase 1 clinical trial is to to assess the safety, tolerability, and systemic exposure of single, twice daily (BID) doses and repeated BID doses of ascending dosing by intranasal administration of Apo-Si-K170AC76 in healthy adult subjects. The primary objective is to evaluate the safety and tolerability of single, BID, and repeated BID, ascending dosing of Apo-Si-K170A-C76 administered intranasally (IN) in healthy adult subjects.
The secondary objective is to evaluate the systemic exposur...